Australia markets open in 2 hours 53 minutes
  • ALL ORDS

    7,299.10
    +43.30 (+0.60%)
     
  • AUD/USD

    0.7802
    +0.0030 (+0.38%)
     
  • ASX 200

    7,066.00
    +42.40 (+0.60%)
     
  • OIL

    65.30
    -0.97 (-1.46%)
     
  • GOLD

    1,869.80
    +2.20 (+0.12%)
     
  • BTC-AUD

    55,793.92
    -1,720.64 (-2.99%)
     
  • CMC Crypto 200

    1,222.40
    -30.74 (-2.45%)
     

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021

  • Oops!
    Something went wrong.
    Please try again later.
Organogenesis Inc.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

CANTON, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2021 financial results will be reported after the market closes on Monday, May 10.

Management will host a conference call at 5:00 p.m. Eastern Time on May 10 to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 9199306. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.

For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 9199306. The webcast will be archived at investors.organogenesis.com.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

CONTACT: Investor Inquiries: Westwicke Partners Mike Piccinino, CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis Lori Freedman lfreedman@organo.com